Kanglin Biotechnology (Hangzhou) Co., Ltd. was founded in 2015 with the goal of translating advances in genetic science into curative treatments for previously incurable diseases. We believe in the groundbreaking potential of genetic medicine and have set ourselves the goal of developing first-in-class and best-in-class gene therapies. Guided by scientific innovation, our aspiration is very simple, to make good medicine for patients.  We are currently developing gene therapies for devastating diseases such as β-thalassemia, Parkinson’s disease, HIV, hemophilia and others. Years of dedicated research and development have yielded initial results. Investigator-initiated trials of our β-thalassemia candidate has shown promising results with best-in-class potential in efficacy and safety in addition to dramatically reduced manufacturing costs, e.g., COGs is roughly lower than that of competitive products by 10x.